Pacific Biosciences Of Stock Current Valuation
| PACB Stock | USD 1.45 0.01 0.68% |
Valuation analysis of Pacific Biosciences helps investors to measure Pacific Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to -10. The current year's Enterprise Value Multiple is expected to grow to -10. Fundamental drivers impacting Pacific Biosciences' valuation include:
Overvalued
Today
Please note that Pacific Biosciences' price fluctuation is extremely dangerous at this time. Calculation of the real value of Pacific Biosciences is based on 3 months time horizon. Increasing Pacific Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pacific Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pacific Stock. However, Pacific Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.45 | Real 1.33 | Target 3.02 | Hype 1.45 | Naive 1.44 |
The real value of Pacific Stock, also known as its intrinsic value, is the underlying worth of Pacific Biosciences Company, which is reflected in its stock price. It is based on Pacific Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pacific Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pacific Biosciences of helps investors to forecast how Pacific stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pacific Biosciences more accurately as focusing exclusively on Pacific Biosciences' fundamentals will not take into account other important factors: Pacific Biosciences of Company Current Valuation Analysis
Pacific Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pacific Biosciences Current Valuation | 709.26 M |
Most of Pacific Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacific Biosciences of is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pacific Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacific Biosciences is extremely important. It helps to project a fair market value of Pacific Stock properly, considering its historical fundamentals such as Current Valuation. Since Pacific Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacific Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacific Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pacific Biosciences of has a Current Valuation of 709.26 M. This is 95.06% lower than that of the Life Sciences Tools & Services sector and 94.29% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.73% higher than that of the company.
Pacific Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacific Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacific Biosciences could also be used in its relative valuation, which is a method of valuing Pacific Biosciences by comparing valuation metrics of similar companies.Pacific Biosciences is currently under evaluation in current valuation category among its peers.
Pacific Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | (1.62) % | ||||
| Current Valuation | 709.26 M | ||||
| Shares Outstanding | 294.32 M | ||||
| Shares Owned By Insiders | 9.30 % | ||||
| Shares Owned By Institutions | 84.98 % | ||||
| Number Of Shares Shorted | 66.69 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 2.77 X | ||||
| Revenue | 154.01 M | ||||
| Gross Profit | 47.67 M | ||||
| EBITDA | (356.38 M) | ||||
| Net Income | (306.74 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 933.93 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 1.79 X | ||||
| Cash Flow From Operations | (259.17 M) | ||||
| Short Ratio | 5.04 X | ||||
| Earnings Per Share | (1.58) X | ||||
| Price To Earnings To Growth | (0.17) X | ||||
| Target Price | 2.67 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 426.76 M | ||||
| Total Asset | 1.75 B | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 647.02 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
| Net Asset | 1.75 B |
About Pacific Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacific Biosciences of's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacific Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacific Biosciences of based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Pacific Biosciences Piotroski F Score and Pacific Biosciences Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.33) | Return On Assets | Return On Equity |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.